CVS Health (CVS) stock in focus as its pharmacy benefit manager CVS Caremark faces $289.9M in damages and penalties for ...

A federal judge has ordered CVS Caremark to pay almost $290 million in damages and penalties after a whistleblower proved the ...

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

A federal judge has ordered CVS Caremark to pay nearly $290 million in damages after determining the pharmacy benefit manager overbilled Medicare for prescription drugs, according to court documents ...

A federal judge has ordered CVS Health's PBM Caremark to pay nearly $290 million after a whistleblower accused the business of overcharging Medicare on prescription drugs more than a decade ago.

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Whistleblower Sarah Behnke's lawsuit leads to $290 million judgment against CVS Caremark for overcharging Medicare on ...

Chief Judge Mitchell Goldberg tripled to $285 million the damages he had ordered CVS Caremark to pay in June, citing the ...

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

Regulators have also imposed $160,000 in fines on Cigna's Express Scripts unit; $66,000 in fines on Rightway PBM Services; ...

Ed DeVaney, a longtime CVS Health® official, is the new president of the Woonsocket, R.I.-based company’s CVS Caremark® pharmacy benefit management business. He previously was named interim ...

CVS’ health insurance segment reported a medical loss ratio — a marker of spending on patient care — of 85.7% in the quarter, higher than analysts expected.